SG3 Management’s Ginkgo Bioworks DNA Stock Holding History

SG3 Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-250	Closed	-$24K	–	339
2022 Q2	$24K	Sell	250 -13,000	-98%	-$1.59M	﹤0.01%	375
2022 Q1	$2.14M	Buy	+13,250	New	+$2.58M	0.06%	289

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

SG3 Management's DNA Position: Q2 2022 in Review

SG3 Management sold out of Ginkgo Bioworks (DNA) in Q2 2022, closing a stake of 1,750 shares — an estimated $213K sold.

SG3 Management first reported a position in DNA in Q1 2022 and held it in 1 quarter. The position peaked at $282K in Q1 2022. 260 funds tracked by Wall St. Rank hold DNA as of Q2 2022.

SG3 Management reported no remaining Ginkgo Bioworks position as of Q2 2022 after selling out during the quarter.
SG3 Management sold 1,750 Ginkgo Bioworks shares in Q2 2022, an estimated $213K.
SG3 Management first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 1 quarter.
SG3 Management's Ginkgo Bioworks position peaked at $282K in Q1 2022.
260 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.